Venus Medtech-B (02500) Sets 31 March 2026 Board Meeting to Approve FY 2025 Results

Bulletin Express03-19

Venus Medtech (Hangzhou) Inc. (stock code: 02500) has announced that its Board of Directors will convene on 31 March 2026. The meeting’s primary agenda is to review and approve the consolidated annual results for the financial year ended 31 December 2025, followed by the publication of the audited figures.

The session will also address any additional corporate matters deemed necessary. According to the disclosure, the company’s current board comprises three executive directors (Lim Hou-Sen, Liqiao Ma and Meirong Liu), two non-executive directors (Ao Zhang and Wei Wang) and three independent non-executive directors (Ting Yuk Anthony Wu, Chi Wai Suen and John Junhua Gu).

The announcement was authorised for issue by Executive Director Mr Lim Hou-Sen on 19 March 2026 in Hangzhou. No further financial details were provided ahead of the scheduled meeting.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment